Abstract Number: 130

Indirect comparison of ixekizumab (IXE) and secukinumab (SEC) using matched-adjusted indirect comparisons (MAIC)

N. Burkhardt, B. Strober, A. Brnabic, A. Schacht,

Meeting: 2017 Dermcoll

Session Information

Date: -

Session Title: Posters

Session Time: -

IXE (anti-interleukin-17A monoclonal antibody with a high binding affinity) is a new treatment for moderate-to-severe psoriasis. We compared efficacy/quality-of-life (QoL) data indirectly between IXE and SEC (anti-interleukin-17A monoclonal antibody) clinical trials using MAIC. The inclusion/ exclusion criteria in one SEC trial were applied to IXE trials. IXE patient data were re-weighted to balance the aggregate data regarding selected baseline characteristic means. We used the Bucher method (BU) and two modified Signorovitch methods (SG) to compare IXE 80 mg every 2 weeks (IXEQ2W) to SEC 300 mg/week via the common comparator (bridge), etanercept, with respect to efficacy (Psoriasis Area Severity Index [PASI]) and QoL (Dermatology Life Quality Index [DLQI]) over the first 12 weeks. PASI90 response rates (RRs) for IXEQ2W were 15.1% (p < 0.001), 13.7% (p = 0.003), and 13.4% (p = 0.005) higher than SEC using the BU, SG total, and SG separate arms methods. PASI100 RRs were significantly higher for IXEQ2W vs. SEC with response differences (RDs) of 14%, 15.2%, and 15% for the three approaches. For PASI75, the RRs were high for both treatments, and IXE was only significantly better using BU (RD = 8.6%, p = 0.044), but not for the SG approaches (RD = 4.3%, p = 0.368; RD = 4%, p = 0.399). For DLQI(0,1), RRs for IXE2QW relative to SEC (differences of 4.1%, 0.6%, and 0.3%) were comparable. Both treatments achieved high RRs for PASI75, with small differences when adjusting for baseline differences. For PASI90 and PASI100, RRs differed significantly, favoring IXE over SEC. Efficacy gains did not translate into significant differences in QoL as measured by DLQI(0,1) at Week 12.